Netherlands Pharmaceuticals & Healthcare Report

Published 14 August 2015

  • 111 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
$1,295.00
Netherlands Pharmaceuticals & Healthcare Report

BMI View: The Netherlands has a well-developed healthcare sector and a highly competitive pharmaceutical industry. With the Dutch economy entering a cyclical growth upswing, we expect higher consumer spending will provide a small boost to pharmaceutical sales in the near term. We forecast the pharmaceutical market will return to growth in 2016, the first time since 2011. Over the long term, medicine demand will be driven by the country ' s ageing population. However, market potential will continue to be dampened by the patent cliff, rising use of cheaper generic products and further drug price restrictions.

Headline Expenditure Projections

  • Pharmaceuticals: EUR5.92bn (USD7.93bn) in 2014 to EUR5.83bn (USD6.41bn) in 2015; -1.5% in local currency terms and -19.2% in US dollar terms. Forecast in line with last quarter.

  • Healthcare: EUR73.31bn (USD98.23bn) in 2014 to EUR74.33bn (USD81.76bn) in 2015; +1.4% in local currency terms and -16.8% in US dollar terms. Forecast revised downwards slightly from last quarter.

Risk/Reward Index

The Netherlands continues to rank in the lower half of BMI's Risk/Reward Index (RRI) for the 15 key Western European markets, ranking 11th in our index for Q415. At 64.7, its overall RRI score remains unchanged from last quarter and is still slightly below the regional average of 66.9. While the country offers drugmakers a relatively low-risk operating environment, poor market prospects - due to pressures on pricing and reimbursement and the market's maturity - will continue to weigh down the country's overall standing.

Key Trends And Developments

June 2015

  • Dutch drugmaker Kiadis Pharma is planning to raise funds for research through the listing of its shares on the Amsterdam and Brussels stock exchanges. The company's lead product, ATIR 101, is currently in Phase II trials for leukaemia. The drug acts by facilitating the transplantation of stem cells from family donors. Trial results are expected in Q116. Furthermore, Kiadis'...

BMI Industry View
7
SWOT
9
Political
11
Economic
12
Operational Risk
13
Industry Forecast
14
Pharmaceutical Market Forecast
14
Table: Pharmaceutical Sales, Historical Data And Forecasts (Netherlands 2011-2019)
16
Healthcare Market Forecast
17
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Netherlands 2011-2019)
20
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Netherlands 2011-2019)
20
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Netherlands 2011-2019)
21
Prescription Drug Market Forecast
22
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Netherlands 2011-2019)
23
Patented Drug Market Forecast
24
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Netherlands 2011-2019)
25
Generic Drug Market Forecast
26
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Netherlands 2011-2019)
27
OTC Medicine Market Forecast
28
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Netherlands 2011-2019)
30
Pharmaceutical Trade Forecast
31
Table: Pharmaceutical Trade Data And Forecasts (Netherlands 2013-2019)
32
Table: Pharmaceutical Trade Data And Forecasts local currency (Netherlands 2013-2019)
32
Key Risks To BMI's Forecast Scenario
33
Macroeconomic Forecasts
35
Economic Analysis
35
Table: GDP Contribution To Growth (Netherlands 2012-2020)
41
Industry Risk Reward Indices
42
Western Europe Risk/Reward Index - Q4 2015
42
Netherlands Risk/Reward Index
47
Rewards
47
Risks
47
Market Overview
49
Industry Trends And Developments
50
Epidemiology
50
Healthcare Sector
52
Table: Healthcare Resources (Netherlands 2009-2014)
54
Table: Healthcare Personnel (Netherlands 2009-2014)
54
Table: Healthcare Activity (Netherlands 2009-2014)
55
Healthcare Funding
55
Health Insurance
55
Table: Key Points Of The Dutch Health Insurance Act, January 1 2006
57
Healthcare Insurance Developments
60
Table: Biosimilars Approved In The EU
60
Research And Development
61
Clinical Trials
62
Biotechnology
64
Regulatory Development
65
Regulatory Developments
66
Intellectual Property Regime
68
Pricing Regime
68
Reimbursement Regime
71
Competitive Landscape
73
Pharmaceutical Industry
73
Table: Pharmaceutical Production, 1995-2010 (EUR '000s)
73
Recent Company Activity
75
Pharmaceutical Wholesale Sector
76
Pharmaceutical Retail Sector
77
Company Profile
80
DSM
80
GlaxoSmithKline
83
Merck & Co
85
Novartis
87
Pfizer
89
Pharming Group
91
Qiagen
94
Sanofi
97
Demographic Forecast
99
Demographic Outlook
99
Table: Population Headline Indicators (Netherlands 1990-2025)
100
Table: Key Population Ratios (Netherlands 1990-2025)
100
Table: Urban/Rural Population & Life Expectancy (Netherlands 1990-2025)
101
Table: Population By Age Group (Netherlands 1990-2025)
101
Table: Population By Age Group % (Netherlands 1990-2025)
102
Glossary
104
Methodology
106
Pharmaceutical Expenditure Forecast Model
106
Healthcare Expenditure Forecast Model
106
Notes On Methodology
107
Risk/Reward Index Methodology
108
Index Overview
109
Table: Pharmaceutical Risk/Reward Index Indicators
109
Indicator Weightings
110

The Netherlands Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Netherlands Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Netherlands pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Netherlands, to test other views - a key input for successful budgeting and strategic business planning in the Dutch pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Dutch pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Netherlands.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%